Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374019 · ClinicalTrials.gov registry record · Phase 2
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
A Phase 2 study, sponsored by Susanne Arnold.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04374019 is a Phase 2 study that was terminated before completion, run by Susanne Arnold. The registered enrollment target is 13 participants.
The verdict
NCT04374019, a Phase 2 study, was terminated before completion, sponsored by Susanne Arnold.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Interventions
- DRUG Ivermectin
- DRUG Artesunate
- DRUG Camostat Mesilate
- DIETARY_SUPPLEMENT Artemesia annua
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374019
The ClinicalTrials.gov registry entry for NCT04374019 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susanne Arnold, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ivermectin is the first listed.
NCT04374019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374019 about?
NCT04374019 is a clinical study titled "Novel Agents for Treatment of High-risk COVID-19 Positive Patients". This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, ar...
What is the current status of trial NCT04374019?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-05-01. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04374019?
The interventions under investigation include: Ivermectin (DRUG), Artesunate (DRUG), Camostat Mesilate (DRUG), Artemesia annua (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04374019?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.